80%Confidence
0Views
FDASource
2026-05-25Date
Summary
Endo USA's recall of buprenorphine injection due to particulate matter poses patient safety risks and potential legal liabilities. This could pressure Endo's pharmaceutical segment and lead to regulatory fines or production delays.
Actionable: Review Endo's supply chain and litigation exposure; consider hedging positions in opioid-related stocks.
AI Confidence: 80%
Data Points
firmENDO USA, Inc.
classificationClass II
statusOngoing
distributionUSA Nationwide
productBuprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now